Q2 2026 saw resumed Ximluci shipments, SEK 46.8 million revenue, and a 5% gross margin, with cost reduction measures expected to impact from mid-2027. U.S. FDA decision for Ximluci is due in October, and new co-development for Xdarzane advances pipeline.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.